Kevin J. Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kevin J. Liu has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Alan Wang
Auckland Bioengineering Institute, The University of Auckland, Auckland, New Zealand
14 shared publications - Amal Thomas
Department of Molecular and Computational Biology, USC David and Dana Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California
14 shared publications Charlotte S. Walmsley
14 shared publicationsDiane S. Kang
14 shared publications- Frank Attenello
Department of Neurological Surgery, University of Southern California, Los Angeles, CA, USA
14 shared publications - James Hicks
Convergent Science Institute in Cancer, University of Southern California, Los Angeles, USA
14 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Springer Nature in Nature Methods
- p. 1-15
Enhanced cfDNA methylation profiling by detection and correction of jagged ends
- 29 October 2026
- Published by Springer Nature in Nature Methods
- p. 1-15
Open AccessEnhanced cfDNA methylation profiling by detection and correction of jagged ends
- Open Access
- 2 October 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 4091-4102
Urine cell-free RNA for bladder cancer detection and treatment response prediction
- 2 October 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 4091-4102
Open AccessUrine cell-free RNA for bladder cancer detection and treatment response prediction
- Top Cited PapersOpen Access
- 19 November 2025
- Published by Springer Nature in Nature
- Vol. 649 (8095) , 152-160
Genetic elements promote retention of extrachromosomal DNA in cancer cells
Extrachromosomal DNA (ecDNA) is a prevalent and devastating form of oncogene amplification in cancer 1,2 . Circular megabase-sized ecDNAs lack centromeres, stochastically segregate during cell division 3–6 and persist over many generations. It has been more than 40 years since ecDNAs were first observed to hitchhike on mitotic chromosomes into daughter cell nuclei, but the mechanism underlying this process remains unclear 3,7 . Here we identify a family of human genomic elements, termed retention elements, that tether episomes to mitotic chromosomes to increase ecDNA transmission to daughter cells. Using Retain-seq, a genome-scale assay that we developed, we reveal thousands of human retention elements that confer generational persistence to heterologous episomes. Retention elements comprise a select set of CpG-rich gene promoters and act additively. Live-cell imaging and chromosome conformation capture show that retention elements physically interact with mitotic chromosomes at regions that are mitotically bookmarked by transcription factors and chromatin proteins. This activity intermolecularly recapitulates promoter–enhancer interactions. Multiple retention elements are co-amplified with oncogenes on individual ecDNAs in human cancers and shape their sizes and structures. CpG-rich retention elements are focally hypomethylated. Targeted cytosine methylation abrogates retention activity and leads to ecDNA loss, which suggests that methylation-sensitive interactions modulate episomal DNA retention. These results highlight the DNA elements and regulatory logic of mitotic ecDNA retention. Amplifications of retention elements promote the maintenance of oncogenic ecDNA across generations of cancer cells, and reveal the principles of episome immortality intrinsic to the human genome.
- 19 November 2025
- Published by Springer Nature in Nature
- Vol. 649 (8095) , 152-160
Top Cited PapersOpen AccessGenetic elements promote retention of extrachromosomal DNA in cancer cells
Extrachromosomal DNA (ecDNA) is a prevalent and devastating form of oncogene amplification in cancer 1,2 . Circular megabase-sized ecDNAs lack centromeres, stochastically segregate during cell division 3–6 and persist over many generations. It has been more than 40 years since ecDNAs were first observed to hitchhike on mitotic chromosomes into daughter cell nuclei, but the mechanism underlying this process remains unclear 3,7 . Here we identify a family of human genomic elements, termed retention elements, that tether episomes to mitotic chromosomes to increase ecDNA transmission to daughter cells. Using Retain-seq, a genome-scale assay that we developed, we reveal thousands of human retention elements that confer generational persistence to heterologous episomes. Retention elements comprise a select set of CpG-rich gene promoters and act additively. Live-cell imaging and chromosome conformation capture show that retention elements physically interact with mitotic chromosomes at regions that are mitotically bookmarked by transcription factors and chromatin proteins. This activity intermolecularly recapitulates promoter–enhancer interactions. Multiple retention elements are co-amplified with oncogenes on individual ecDNAs in human cancers and shape their sizes and structures. CpG-rich retention elements are focally hypomethylated. Targeted cytosine methylation abrogates retention activity and leads to ecDNA loss, which suggests that methylation-sensitive interactions modulate episomal DNA retention. These results highlight the DNA elements and regulatory logic of mitotic ecDNA retention. Amplifications of retention elements promote the maintenance of oncogenic ecDNA across generations of cancer cells, and reveal the principles of episome immortality intrinsic to the human genome.
- Top Cited Papers
- 16 April 2025
- Published by Springer Nature in Nature
- Vol. 641 (8063) , 759-768
An ultrasensitive method for detection of cell-free RNA
Sensitive methods for detection of cell-free RNA (cfRNA) could facilitate non-invasive gene expression profiling and monitoring of diseases1,2,3,4,5,6. Here we describe RARE-seq (random priming and affinity capture of cfRNA fragments for enrichment analysis by sequencing), a method optimized for cfRNA analysis. We demonstrate that platelet contamination can substantially confound cfRNA analyses and develop an approach to overcome it. In analytical validations, we find RARE-seq to be approximately 50-fold more sensitive for detecting tumour-derived cfRNA than whole-transcriptome RNA sequencing (RNA-seq), with a limit of detection of 0.05%. To explore clinical utility, we profiled 437 plasma samples from 369 individuals with cancer or non-malignant conditions and controls. Detection of non-small-cell lung cancer expression signatures in cfRNA increased with stage (6 out of 20 (30%) in stage I; 5 out of 8 (63%) in stage II; 10 out of 15 (67%) in stage III; 80 out of 96 (83% sensitivity) in stage IV at 95% specificity) and RARE-seq was more sensitive than tumour-naive circulating tumour DNA (ctDNA) analysis. In patients with EGFR-mutant non-small-cell lung cancer who developed resistance to tyrosine kinase inhibitors, we detected both histological transformation and mutation-based resistance mechanisms. Finally, we demonstrate the potential utility of RARE-seq for determination of tissue of origin, assessing benign pulmonary conditions and tracking response to mRNA vaccines. These results highlight the potential value of ultrasensitive cfRNA analysis and provide proof of concept for diverse clinical applications.
- 16 April 2025
- Published by Springer Nature in Nature
- Vol. 641 (8063) , 759-768
Top Cited PapersAn ultrasensitive method for detection of cell-free RNA
Sensitive methods for detection of cell-free RNA (cfRNA) could facilitate non-invasive gene expression profiling and monitoring of diseases1,2,3,4,5,6. Here we describe RARE-seq (random priming and affinity capture of cfRNA fragments for enrichment analysis by sequencing), a method optimized for cfRNA analysis. We demonstrate that platelet contamination can substantially confound cfRNA analyses and develop an approach to overcome it. In analytical validations, we find RARE-seq to be approximately 50-fold more sensitive for detecting tumour-derived cfRNA than whole-transcriptome RNA sequencing (RNA-seq), with a limit of detection of 0.05%. To explore clinical utility, we profiled 437 plasma samples from 369 individuals with cancer or non-malignant conditions and controls. Detection of non-small-cell lung cancer expression signatures in cfRNA increased with stage (6 out of 20 (30%) in stage I; 5 out of 8 (63%) in stage II; 10 out of 15 (67%) in stage III; 80 out of 96 (83% sensitivity) in stage IV at 95% specificity) and RARE-seq was more sensitive than tumour-naive circulating tumour DNA (ctDNA) analysis. In patients with EGFR-mutant non-small-cell lung cancer who developed resistance to tyrosine kinase inhibitors, we detected both histological transformation and mutation-based resistance mechanisms. Finally, we demonstrate the potential utility of RARE-seq for determination of tissue of origin, assessing benign pulmonary conditions and tracking response to mRNA vaccines. These results highlight the potential value of ultrasensitive cfRNA analysis and provide proof of concept for diverse clinical applications.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 (xlsx) from Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
List of unique genes upregulated in CTC-derived brain metastases
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 (xlsx) from Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
List of unique genes upregulated in CTC-derived brain metastases
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
File includes supplementary figures S1 to S5
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
File includes supplementary figures S1 to S5
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
Includes supplementary tables S1, S2, S5, S6, S7 and S9
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
Includes supplementary tables S1, S2, S5, S6, S7 and S9